

Minutes

Drug Utilization Review Board Meeting

DATE: December 13, 2023



Meeting Purpose: Quarterly Drug Utilization Board Meeting
Meeting opened at 6:00 p.m. by Timothy Fensky, RPh.

The meeting was conducted under Massachusetts Public Meeting Law requirements.

Attendance: Mehmet Furkan Burbak, MD; Melissa Coyle, PharmD; Timothy Fensky, RPh; Colleen Labelle, MSN, RN-BC, CARN; Lori Lewicki, RPh; Greg Low, RPh, PhD; Sarah M McGee, MD; Laura Spring, MD; Karen Ryle, MS, RPh; Christy Stine, MD, PhD

Absent: James Gagnon, RPh, PharmD; Rebekah Rice, RPh, CDCES

Agenda Items:

- Welcome and Introductory Remarks
- Clinical Team Update
- Minutes
- Cerebral Stimulants and Miscellaneous ADHD Medications Quality Assurance Analysis
- MHDL Update
- DUR Operational Update
- MassHealth Update
- Open Forum

Agenda Item	Discussion	Conclusions/Follow-up
Clinical Team Update	<u>Clinical Team Update by Dr. Mark Tesell</u> This overview provided an update of projects and accomplishments of the clinical pharmacist team of the MassHealth Drug Utilization Review Program and Office of Clinical Affairs.	<u>Follow-up</u> Informational/Advisory
Action	Discussion <ul style="list-style-type: none">• Reviewed clinical projects and accomplishments for fiscal year 2023• Presented an overview of disseminated work related to the MassHealth pharmacy program	<u>Conclusion</u> The board reviewed and accepted the presentation.

Agenda Item

Discussion

		Conclusions/Follow-up
Minutes	Motion to approve the minutes for September 2023 was made by Timothy Fensky, RPh and seconded by Christy Stine, MD, PhD.	<u>Follow-up</u> Minutes are approved.

Agenda Item	Discussion	Conclusions/Follow-up
Cerebral Stimulants and Miscellaneous ADHD Medications Quality Assurance Analysis	<p><u>Cerebral Stimulants and Miscellaneous ADHD Medications Quality Assurance Analysis by Dr. Amy Dionne</u></p> <p>This overview was an evaluation of current medical literature and provided a brief overview of new guideline recommendations in this disease state.</p>	<p><u>Follow-up</u> Informational/Advisory</p>
Action	<p>Discussion</p> <ul style="list-style-type: none"> Reviewed Guidelines for Treatment of ADHD Discussed Trends in Utilization Evaluated Prior Authorization Requests Recommended Guideline Changes Discussed Hot Topics and Looking to the Future: Pipeline <p>Recommendations</p> <ul style="list-style-type: none"> Remove PA from clonidine ER and maintain quantity limit of 4 units/day Add quantity limits to select liquid preparations based on FDA-Approved dosing Add Relexxi to the MassHealth Drug List as requiring PA <p>Questions</p> <p>The DUR Board discussed the shortages of stimulant medications and concerns with stimulants contributing to overdose deaths.</p>	<p><u>Conclusion</u> The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
	<u>MHDL Update by Dr. Elda Morava</u>	<p><u>Follow-up</u> Informational/Advisory</p>

Agenda Item	Discussion	Conclusions/Follow-up
MassHealth Drug List (MHDL) Update	MHDL overview included new additions, changes in prior authorization (PA) status, and related attachment updates to be implemented with a recent publication rollout.	
Action	<p>Discussion</p> <ul style="list-style-type: none"> • There were seven additions and eight changes to PA status to the MHDL Drug list effective January 2, 2024. • As of January 1, 2024, obesity drugs were added to the MHDL, as they are no longer excluded per regulation 130 CMR 406.413(B). • There were additional changes to the Brand Name Preferred Over Generic List, the 90 Days Initiative List, the Non-Drug Product List, and the Supplemental Rebate/Preferred Drug List. 	<p><u>Conclusion</u></p> <p>The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
DUR Operational Update	<p><u>DUR Operational Update by Dr. Kristen Danis</u></p> <p>DUR operational overview included statistics associated with PA review and PA response, and call center metrics.</p>	<p><u>Follow-up</u></p> <p>Informational/Advisory</p>
Action	<p>Discussion</p> <ul style="list-style-type: none"> • The operational statistics including prior authorization and call center metrics up to September 30, 2023, were discussed. • All metrics met or exceeded service level agreements. 	<p><u>Conclusion</u></p> <p>The board reviewed and accepted the presentation.</p>

Agenda Item	Discussion	Conclusions/Follow-up
MassHealth Update	<p><u>MassHealth Update by Dr. Kimberly Lenz</u></p> <p>MassHealth Update is a summary of recent developments in MassHealth in the context of pharmacy, managed care, or public health.</p>	<p><u>Follow-up</u></p> <p>Informational/Advisory</p>

Agenda Item	Discussion	Conclusions/Follow-up
Action	Discussion <ul style="list-style-type: none"> Reviewed current clinical program initiatives Provided direct negotiation status update Discussed operational updates 	<u>Conclusion</u> The board reviewed and accepted the presentation.

Agenda Item	Discussion	Conclusions/Follow-up
Open Forum	<u>Open Forum</u>	<u>Follow-up</u> Informational/Advisory
Action	Discussion <ul style="list-style-type: none"> This presentation was tabled until the next DUR Board meeting. 	<u>Conclusion</u> N/A

Meeting adjourned at 8:00 p.m.

Respectfully submitted by Mylissa Price

Date: _____